Navigation Links
FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
Date:2/1/2012

s to recommend consideration of at least three years of adjuvant therapy with Gleevec for patients with high-risk GIST(2).

In addition to extending the Gleevec label to three-year treatment duration in patients with KIT+ GIST after surgery, the FDA has agreed that all accelerated post-approval commitments for this indication have been met, confirming the clinical benefit of adjuvant treatment with Gleevec.

Study details
The SSG XVIII clinical trial was conducted by the Scandinavian Sarcoma Group (SSG) and the Sarcoma Group of the Arbeitsgemeinschaft Internistische Onkologie (AIO). This trial was a multicenter, prospective, randomized study for the evaluation of adjuvant treatment with Gleevec of histologically confirmed KIT+ GIST(5).

The primary endpoint of the study was to compare, within the first five years, recurrence-free survival in patients with a greater than 50% estimated risk of GIST disease recurrence, following diagnosis and treatment with adjuvant Gleevec for either 12 or 36 months. The secondary endpoints included overall survival and treatment safety(1).

Three hundred ninety-seven patients entered the study. Inclusion criteria for risk of recurrence was defined as tumor diameter >5.0 cm and mitotic count >5/50 high power fields (HPFs); or tumor diameter >10.0 cm, any mitotic count; or tumor of any size with a mitotic count >10/50 HPFs; or tumors ruptured into the peritoneal cavity.

Recurrence-free survival was longer in the 36-month group compared to the 12-month group (HR 0.46, 95% CI 0.32-0.65; p<0.0001). Patients assigned to 36 months of Gleevec after surgery had longer overall survival (HR 0.45, 95% CI 0.22-0.89; p=0.0187). Almost all patients experienced side effects while taking Gleevec. Gleevec was generally well tolerated. The proportion of patients who discontinued Gleevec during the assigned treatment period for reasons other than GIST recurrence was 26% over the full three yea
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 3, 2015 Redwood ... Broda Technologies Co., Ltd., operating in both the US ... company,s proprietary IntelliGel ® supramolecular hydrogel technology in ... and other ophthalmic therapies. The Broda technology offers many ... is a free-forming liquid and with low concentrations of ...
(Date:7/2/2015)... 2, 2015 Leading organizations have increasingly ... product and market insights in internal market research ... studies, it is essential for executives to fully ... to capture critical business-related insights. According ... Practices, LLC, most benchmarked companies find it impossible ...
(Date:7/2/2015)... CHAPEL HILL, N.C. , July 2, 2015 /PRNewswire/ ... industry. Because of its leading role in educating thought ... the functions that can heavily influence how well a ... to a new study from research and consulting leader ... Medical Affairs leaders need to focus on are early ...
Breaking Medicine Technology:Redwood Pharma Licenses Novel Hydrogel Drug Delivery Technology From Broda Technologies 2Leveraging Employee Insights to Produce Cutting-Edge Market Research 2Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2
... Texas, Feb. 23, 2012   ULURU Inc. (NYSE ... Goods Certificate has been issued by the Therapeutic Goods ... Commenting on the approval in Australia, Kerry P. ... another important milestone in the worldwide commercialization of Altrazeal®.  ...
... Feb. 23, 2012 A new imaging efficiency ... Medicaid Services (CMS) to reduce CT scans in ... are performing CT scans inappropriately, according to a ... of Emergency Medicine ("Assessment of Medicare,s Imaging ...
Cached Medicine Technology:ULURU Inc. Announces Approval to Market Altrazeal® in Australia 2ULURU Inc. Announces Approval to Market Altrazeal® in Australia 3Government Rule Designed to Limit CT Scans in ERs Is Unreliable, Invalid and Inaccurate, Says ACEP 2
(Date:7/3/2015)... MO (PRWEB) , ... July 03, 2015 , ... Talcum ... website to replace their existing Talcum Powder Cancer Lawsuit Center website. Just as the ... talcum powder lawsuit news , offering timely lawsuit updates and ovarian cancer warning information. ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Every year, One-to-1 ... Train-a-Thon where they provide members of the Red Deer community with free fitness training ... of fitness training, games, food, events and entertainment raised thousands of charity dollars and ...
(Date:7/2/2015)... ... 02, 2015 , ... Following the recent report by JAMA Internal Medicine ... merely overweight Americans, Samir Becic emphatically declared a war on obesity in the United ... Becic said. "We must understand the magnitude of this discovery. For that reason, I ...
(Date:7/2/2015)... ... , ... In 2012, Patrick Achebe realized that the gift of poetry was fully in him, ... his first poem, and three years later he was publishing an entire book of poetry. ... the world. "I have always believed that the best way to lift yourself up, is ...
(Date:7/2/2015)... ... July 02, 2015 , ... Six months ahead of ... cross-country walk to raise awareness and money for the Pulmonary Hypertension Association (PHA). ... at PHA’s headquarters near Washington, D.C. by mid-September. He left Glasgow, Mont. yesterday morning ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3
... than 27 million adults currently suffer from osteoarthritis, which is ... have been unable to diagnose patients with arthritis until they ... By the time these symptoms are present, it is ... to be effective. Now, a research team from the ...
... By Alan Mozes HealthDay Reporter , TUESDAY, May ... restored partial mobility to the hand of a quadriplegic patient. ... bone in his neck, and it was the specific location ... the spine itself. Instead, the team focused on the ...
... Journal of Thoracic Oncology says molecular biomarkers in ... additional predictive technique for lung cancer screening. , Since ... the positive CT screening results were false positive, scientists have ... research focused on a way to determine if the nodules ...
... HealthDay Reporter , TUESDAY, May 15 (HealthDay News) -- Should Americans ... it to determine whether they,re infected with the virus that causes ... plans to debate this question Tuesday, and the answer the panel ... HIV testing. FDA advisory panel recommendations are not binding, but ...
... Alberta provides new insight into treatment patterns for people ... will help physicians improve care strategies for patients provincewide. ... School of Public Health, says the study of more ... step to addressing gaps in care and ensuring that ...
... death rate in older Americans is likely the effect ... from the Johns Hopkins Center for Injury Research and ... mortality rate occurred immediately following the 1999 introduction of ... suggesting a major change in the way deaths were ...
Cached Medicine News:Health News:New biomarker test predicts arthritis at much earlier stage, MU researchers say 2Health News:Doctors Restore Some Hand Function to Quadriplegic Patient 2Health News:Doctors Restore Some Hand Function to Quadriplegic Patient 3Health News:FDA Panel to Consider At-Home HIV Test 2Health News:FDA Panel to Consider At-Home HIV Test 3Health News:Study highlights need for coordination of care in stage 2 and 3 rectal cancer treatment 2Health News:Study highlights need for coordination of care in stage 2 and 3 rectal cancer treatment 3Health News:Reported increase in older adult fall deaths due to improved coding 2
... Assisted Lipoplasty Device uses a 2-mm reciprocating movement ... movement of the cannula in tissue. So less ... fibrous tissue. That makes the lipoplasty procedure easier ... your mind to learn that the PAL® is ...
... in.hg.@sea level. Incredibly quiet, yet very powerful. ... systems at one time eliminates the need ... Standard canister set-up is for Abbott 2000ml ... c-UL and CE marks. Includes a wireless ...
... cohesive is a new term being used today to ... more liquid fill that may have been used in ... new science, this is not new technology cohesive ... describe the sticking together nature of the gel. All ...
This Implant enhances and restores the nasal contour, The large selection of sizes with a variety of flares and lengths allows for more individualized results...
Medicine Products: